Developing mechanistic insights into cardiovascular cell therapy: Cardiovascular Cell Therapy Research Network Biorepository Core Laboratory rationale

详细信息    查看全文

• 作者：Claudia  ; Zierold PhD^a ;   ; ^g ; Marjorie A.  ; Carlson^a ;   ; ^g ; Udo C.  ; Obodo BS^a ;   ; ^g ; Elizabeth  ; Wise BS^b ;   ; ^g ; Victor A.  ; Piazza BS^a ;   ; ^g ; Marshall W.  ; Meeks^a ;   ; ^g ; Rachel W.  ; Vojvodic MPH^c ;   ; ^g ; Sarah  ; Baraniuk PhD^c ;   ; ^g ; Timothy D.  ; Henry MD^a ;   ; ^d ;   ; ^g ; Adrian P.  ; Gee PhD^e ;   ; ^g ; Stephen G.  ; Ellis MD^f ;   ; ^g ; Lemuel A.  ; Moyé ; MD^c ;   ; ^g ;   ; ^{lemmoye@msn.com} ; Carl J.  ; Pepine MD ; PhD^b ;   ; ^g ; Christopher R.  ; Cogle MD^b ;   ; ^g ;   ; ^h ; Doris A.  ; Taylor PhD^a ;   ; ^g ;   ; ^h
• 刊名：American Heart Journal
• 出版年：2011
• 出版时间：December 2011
• 年：2011
• 卷：162
• 期：6
• 页码：973-980
• 全文大小：1045 K

文摘

Moderate improvements in cardiac performance have been reported in some clinical settings after delivery of bone marrow mononuclear cells to patients with cardiovascular disease. However, mechanistic insights into how these cells impact outcomes are lacking. To address this, the National Heart, Lung and Blood Institute (NHLBI) Cardiovascular Cell Therapy Research Network (CCTRN) established a Biorepository Core for extensive phenotyping and cell function studies and storing bone marrow and peripheral blood for 10 years. Analyzing cell populations and cell function in the context of clinical parameters and clinical outcomes after cell or placebo treatment empower the development of novel diagnostic and prognostics. Developing such biomarkers that define the safety and efficacy of cell therapy is a major Biorepository aim.